Anna studied Biology, with an emphasis on Cell/Molecular/Developmental Biology at the University of Crete, Greece. During her PhD in Queen Mary, University of London she worked on the knockout of Flavin-containing monoxygenase 5 (Fmo5) gene of the mouse, which eventually led to the identification of Fmo5 as a regulator of metabolic aging. As a Postdoc at the Universities of Ioannina, Greece and the University of Cambridge, UK she worked on the role of cell-surface receptors (Wnt/Notch/FGF4) and adherens junctions in the fate specification of mES cells and mES-derived multipotent cardiac progenitors. She also contributed in the development of an ES-cell-based expression and reporting system for the selection of antibodies affecting cell-surface receptor signalling and controlling stem cell differentiation. Anna joined the BMC Series as a Manuscript Editor in March 2019 and is based in Springer Nature’s London office.
Akila Sridhar obtained her Ph.D from the University of Aberdeen, UK (funded by Cancer Research UK), has a further three years postdoctoral experience as an EMBO Long-term Fellow at Instituto Gulbenkian de Ciência (IGC), Portugal. Her interests cover molecular genetics, cellular biology, biochemistry, developmental biology and telomere biology. After over eleven years of research experience, mainly as a molecular biologist, working with different model systems, she joined the BMC Series as a Locum Editor in September 2018. She has been the Editor of BMC Biotechnology since February 2019 and is based in Springer Nature’s London office.
Anna Melidoni, Manuscript Editor
Peter J. Punt, PhD is Chief Technology Officer of Dutch DNA Biotech BV, a fungal biotechnology technology provider and contract research company situated in the Netherlands. In 1992 he obtained his PhD at the University of Amsterdam on molecular genetic tool development for fungal gene expression. In 2008 he was appointed at Leiden University in the chair of Industrial Biotechnology again focusing on fungal biotechnology. After a career of more than 30 years at TNO, the Dutch Organisation for Applied scientific research, where he was responsible for designing, acquiring and implementing projects with international biotechnology principals, in 2015 together with colleagues created Dutch DNA Biotech, as a spin-out from TNO. He published about 125 peer-reviewed papers (h-index 45) and 20 patent applications. He was appointed section editor for BMC Biotechnology in 2012.
Dr. Claessen is an associate professor at Leiden University, and section editor for BMC Biotechnology since 2015. His team addresses fundamental questions related to multicellular growth and development in filamentous bacteria called actinomycetes. These bacteria produce a vast arsenal of useful metabolites, including many clinically relevant antibiotics. By making use of genetic, biochemical, cell-biological, and various next-generation sequencing technologies his team uses a multidisciplinary approach to understand and control the physiology of these bacteria. Ultimately, this knowledge is used to improve the productivity of these useful microorganisms.
Dr. Marko Radic is an Associate Professor in the UTHSC Department of Microbiology, Immunology and Biochemistry. His research focus centers on the mechanisms leading to autoimmune disease, with an emphasis on disorders that are diagnosed and mediated by autoantibodies. Work from his laboratory has contributed toward understanding the mechanisms of Systemic Lupus Erythematosus, Rheumatoid Arthritis, Anti-Phospholipid Syndrome, Felty’s Syndrome and Sjögren’s Syndrome. His lab works on recombinant and monoclonal antibodies, chimeric antigen receptors, B cells, T cells and neutrophils. The lab searches for connections between individual protein or nucleic acid autoantigens, their post-translational modifications, immune activation, inflammation and specific disease manifestations.
- Instructions for Authors
- Editorial Board
- Sign up for article alerts and news from this journal
As a result of the significant disruption that is being caused by the COVID-19 pandemic we are very aware that many researchers will have difficulty in meeting the timelines associated with our peer review process during normal times. Please do let us know if you need additional time. Our systems will continue to remind you of the original timelines but we intend to be highly flexible at this time.